TG Therapeutics (TGTX) Director Laurence Charney Sells 5,000 Shares

What Happened

• Laurence N. Charney, a director of TG Therapeutics (TGTX), disposed of 5,000 shares on 2026-09-10. The volume-weighted average price reported was $54.96, for gross proceeds of approximately $274,800. The filing indicates the shares were sold by the company’s restricted stock administrator to satisfy Mr. Charney’s income tax obligations.

Key Details

• Transaction date: 2026-09-10 (sale)
• Price: VWAP $54.96 (price range reported $54.92–$54.99; reporting person can provide per-price breakdown on request)
• Shares sold: 5,000; Gross proceeds: ~$274,800
• Reason noted: Sale executed by restricted stock administrator to satisfy income tax withholding (tax withholding, F1/F3)
• Shares owned after transaction: Not specified in this Form 4
• Filing date: 2026-09-14 — appears to be later than the standard two-business-day Form 4 filing requirement (filing delay noted)

Context

• The filing identifies this as a tax-withholding sale of restricted shares rather than a discretionary open-market sale by the insider; such transactions are commonly routine to satisfy tax obligations and do not necessarily indicate a change in the insider’s view of the company. The filing’s footnotes clarify the VWAP pricing methodology and that some holdings include restricted shares that vest over time.